Finance

Lists
IOVA:NASDAQ
Iovance Biotherapeutics Inc
$10.37
+1.17%
(+0.12) 1D
Sep 21, 11:22:41 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IOVA...
Open
$10.43
High
$10.64
Low
$10.17
Mkt. cap
4.70B
Avg. vol.
15.89M
Volume
3.86M
52-wk high
$10.98
52-wk low
$1.76
EPS
-$0.72
Beta
0.83
Shares outstanding
452.97M
No. of employees
975
Open
$10.43
High
$10.64
Low
$10.17
Mkt. cap
4.70B
Avg. vol.
15.89M
Volume
3.86M
52-wk high
$10.98
52-wk low
$1.76
EPS
-$0.72
Beta
0.83
Shares outstanding
452.97M
No. of employees
975
News stories
From web sources and news partners
Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer. Wikipedia
About Iovance Biotherapeutics Inc
CEO-
Employees975
Founded2007
HeadquartersSan Carlos, California, United States
SectorBiotechnology
Websiteiovance.com
Analyst ratings
Based on 7 analysts giving stock ratings to IOVA in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for IOVA in the last 3 months.
Highest
Current $10.37
$15.00 (+44.65%)
Average
$9.43 (-9.07%)
Lowest
$6.00 (-42.14%)
Analyst
Recommendation
Action
Price target
Projected
Date
Etzer Darout
Barclays
Buy
Maintained
$15.00
+44.6%
09/17/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
$10.00
-3.6%
08/25/2026
David Dai
UBS
Hold
Reiterated
$7.00
-32.5%
08/20/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$11.00
+6.1%
08/17/2026
Colleen M. Kusy
Robert W. Baird
Hold
Maintained
$6.00
-42.1%
08/07/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$8.00
-22.9%
08/07/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$9.00
-13.2%
08/06/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$7.00
-32.5%
08/06/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$10.00
-3.6%
06/22/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$14.00
+35%
05/07/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
$14.00
+35%
02/25/2026
Asthika Goonewardene
Truist Financial
Hold
Maintained
-
-
02/25/2026
Andrea Newkirk
Goldman Sachs
Sell
Maintained
$2.00
-80.7%
02/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
67.46M
86.77M
71.43M
99.31M
Cost of goods sold
38.48M
43.11M
42.50M
43.60M
Cost of revenue
38.48M
43.11M
42.50M
43.60M
Research and development expenses
75.17M
71.20M
62.49M
58.85M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34.56M
36.40M
38.95M
39.27M
Operating expense
118.74M
117.12M
109.98M
107.62M
Total operating expenses
157.21M
160.23M
152.47M
151.22M
Operating income
-89.76M
-73.46M
-81.04M
-51.90M
Other non operating income
-
-2.71M
-
-
EBT including unusual items
-93.66M
-71.72M
-79.71M
-48.69M
EBT excluding unusual items
-88.52M
-73.06M
-80.83M
-48.69M
Income tax expense
-2.40M
184.00K
-665.00K
-1.37M
Effective tax rate
2.57%
-0.26%
0.83%
2.82%
Other operating expenses
-
-
-
-
Net income
-91.25M
-71.90M
-79.04M
-47.32M
Net profit margin
-135.28%
-82.87%
-110.66%
-47.64%
Earnings per share
-0.25
-0.18
-0.19
-0.11
Interest and investment income
1.24M
3.10M
213.00K
3.22M
Interest expense
-
-
-
-
Net interest expenses
1.24M
3.10M
213.00K
3.22M
Depreciation and amortization charges
9.01M
9.52M
8.54M
9.50M
EBITDA
-81.00M
-63.53M
-72.50M
-42.40M
Gain or loss from assets sale
-
-
28.00K
642.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps